Gul Sema Yıldıran Keskin, İ. Ertürk, M. Aykan, R. Acar, Aysegul Dumludag, Alper Topal, Caglar Koseoglu, Omer Faruk Kuzu, Ece Ornek, N. Karadurmuş
{"title":"High dose chemotherapy and autologous stem cell transplantation for salvage therapy of relapsed /refractory germ cell tumors; a single center experience.","authors":"Gul Sema Yıldıran Keskin, İ. Ertürk, M. Aykan, R. Acar, Aysegul Dumludag, Alper Topal, Caglar Koseoglu, Omer Faruk Kuzu, Ece Ornek, N. Karadurmuş","doi":"10.1159/000538660","DOIUrl":"https://doi.org/10.1159/000538660","url":null,"abstract":"PURPOSE\u0000The optimal management of relapsed/refractory germ cell tumors remains unsettled. In this study, we aimed to evaluate the efficacy of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as salvage therapy in patients who progressed after at least one line of cisplatin-based chemotherapy.\u0000\u0000\u0000METHODS\u0000We retrospectively reported the results of 133 patients who underwent HDCT and ASCT as salvage therapy from 2016 to 2021. Patients received 3 cycles of paclitaxel, ifosfomide and cisplatin (TIP) regimen as induction and 1 cycle of carboplatin 700 mg/m2 on days 1 to 3 plus etoposide 750 mg/m2 on days 1 to 3, followed by ASCT. Demographic and clinicopathological features of patients, the International Germ Cell Cancer Collaborative Group (IGCCCG) risk group at diagnosis, serum alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (HCG) levels before HDCT, treatment related complications and survival outcomes were recorded.\u0000\u0000\u0000RESULTS\u0000The median age of the patients was 31 (range 18-62). The median follow-up was 31.1 months (95% CI, 28.9 to 33.3 months). During the median follow-up period, 74 of the 133 patients were still alive, and 63 of these were in complete remission. The median progression-free survival (PFS) was 25.8 months (95% CI, 8.1-43.4 months). The 2-year PFS rate was 50.3% and the 2-year overall survival rate was 60.8%. Variables that remained statistically significant in multivariable analysis and were associated with poor prognosis were mediastinal primary tumor location, presence of brain metastases, and higher AFP and HCG levels at baseline.\u0000\u0000\u0000CONCLUSION\u0000One course of HDCT and ASCT after induction with TIP is an effective and feasible treatment option for salvage treatment of relapsed/refractory germ cell tumors, with cure rates of up to 60%.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140739970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with focus on perioperative therapy, radiotherapy and BiTEs.","authors":"Marcel Kemper, Puyan Soltani Germy, Fabian Acker, Jingting Luan, F. Griesinger, Amanda Tufman, Cornelia Kropf-Sanchen, T. Overbeck, Annalen Bleckmann, Miriam Blasi","doi":"10.1159/000538662","DOIUrl":"https://doi.org/10.1159/000538662","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140742519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nargiz Majidova, Murat Sarı, Fatma Akdag Kahvecıglu, Erkan Ozcan, Mutıanur Ozkorkmaz Akdag, Akıf Dogan, Sedat Yıldırım, Sermın Dınc Sonusen, Emıl Yunusov, Alper Yaşar, A. Celebı, Nadiye Sever, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Guren, R. Arıkan, S. Isik, O. Balvan, Ç. Geredeli, K. Uygun, İ. Hacıbekiroğlu, Osman Kostek, I. V. Bayoglu
{"title":"Clinicopathologic Features And Efficacy Of Induction Chemotherapy In Nasopharyngeal Carcinoma: Real-World Experience.","authors":"Nargiz Majidova, Murat Sarı, Fatma Akdag Kahvecıglu, Erkan Ozcan, Mutıanur Ozkorkmaz Akdag, Akıf Dogan, Sedat Yıldırım, Sermın Dınc Sonusen, Emıl Yunusov, Alper Yaşar, A. Celebı, Nadiye Sever, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Guren, R. Arıkan, S. Isik, O. Balvan, Ç. Geredeli, K. Uygun, İ. Hacıbekiroğlu, Osman Kostek, I. V. Bayoglu","doi":"10.1159/000537988","DOIUrl":"https://doi.org/10.1159/000537988","url":null,"abstract":"INTRODUCTION\u0000Nasopharyngeal carcinoma (NPC) accounts for 0.01% of all carcinomas, and 70% of patients have locally advanced disease with a poor prognosis. The mainstay therapy is chemoradiotherapy (CRT), and concurrent administration of platinum-based agents and irradiation provides high local control rates. However, induction (neoadjuvant) chemotherapy (ICT) prior to chemoradiotherapy is recommended for large tumors with a high tumor burden at category 1 level. For induction chemotherapy, platinum-based doublet or triplet combination regimens are recommended. Selected patients with high tumor burden at the time of diagnosis who did not receive induction chemotherapy before chemoradiotherapy were given adjuvant (consolidation) therapy after chemoradiotherapy. This multi-center study aims to share our experience in treatment of NPC and evaluate the factors associated with survival.\u0000\u0000\u0000METHODS\u0000The study included patients diagnosed with NPC who were followed and treated between 2008 and 2022. 142 patients from 6 centers were evaluated. The factors associated with disease-free survival (DFS) overall survival (OS) were evaluated.\u0000\u0000\u0000RESULTS\u0000The median age of our patients was 51 years (IQR: 16-81 years), and the male:female ratio was 2.5:1. A majority of patients (71%) had stage 3-4 disease. They had locally advanced disease, and 48 patients (34%) received induction chemotherapy. Twenty patients (14%) received adjuvant therapy. The median follow-up was 41 months (range, 2.7 to 175.1 months). The median DFS in NPC was 92.6 months (range, 71.9 to 113.3 months), with the 40th month DFS of 70.9%. The median OS was 113 months (range, 91 to 135 months), with the 40th month OS of 84.7%. Median DFS was 95.3 months (range, 64.2 to 126.4 months) in patients who received induction chemotherapy before CRT, which was longer than in the CRT-only group (p=0.6). DFS at the 40th month was 75.1% in patients treated with induction chemotherapy compared to 65.1% in the CRT-only group. Median OS was 117 months (range, 92 to 142 months) in patients receiving induction chemotherapy, which was longer than in the CRT-only group (p=0.4). OS at the 40th month was 86.7% in patients receiving ICT, but 83.6% in the CRT-only group.\u0000\u0000\u0000CONCLUSIONS\u0000Both objective response rate (ORR) and survival were longer in patients who radiologically responded to chemoradiotherapy following induction chemotherapy. Non-response to induction chemotherapy is a negative predictive indicator. The role of induction chemotherapy in locally advanced NPC is increasing.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140751381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Heinrich, Volker Heinemann, S. Stintzing, Lothar Müller, T. Ettrich, P. Buechner-Steudel, Michael Geissler, Jörg Trojan, N. Moosmann, Gunnar Folprecht, Johannes Schmidt, S. Kanzler, Frank Kullmann, Jean-Charles Moulin, Jens Werner, Martin K Angele, Victoria Probst, S. Held, C. Schulz, Myrto Boukovala
{"title":"Adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction - A multicenter phase I/II feasibility study (GMBH-STO-0114).","authors":"K. Heinrich, Volker Heinemann, S. Stintzing, Lothar Müller, T. Ettrich, P. Buechner-Steudel, Michael Geissler, Jörg Trojan, N. Moosmann, Gunnar Folprecht, Johannes Schmidt, S. Kanzler, Frank Kullmann, Jean-Charles Moulin, Jens Werner, Martin K Angele, Victoria Probst, S. Held, C. Schulz, Myrto Boukovala","doi":"10.1159/000538143","DOIUrl":"https://doi.org/10.1159/000538143","url":null,"abstract":"INTRODUCTION\u0000S-1 has been shown to be an effective adjuvant treatment option for East Asian patients who underwent gastrectomy for stage II/III gastric cancer. We conducted a phase I/II study to evaluate the feasibility, tolerability and efficacy of administering S-1 in the adjuvant setting after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (EGJ) in Caucasian patients.\u0000\u0000\u0000METHODS\u0000In this single-cohort, open-label, phase I/II trial, we enrolled patients with locally advanced adenocarcinoma of the stomach or EGJ having undergone R0-resection with or without neoadjuvant treatment. One treatment cycle consisted of oral S-1 (30mg/m² bid) for 14 days. Cycles were repeated every 3 weeks for 18 cycles (54 weeks). Primary endpoint was feasibility and tolerability. Safety was evaluated according to the common toxicity criteria adverse events 4.0 criteria. Secondary endpoints were one-year relapse-free survival rate, relapse-free survival (RFS) and overall survival (OS).\u0000\u0000\u0000RESULTS\u0000Between 10/2015 and 02/2018, 32 patients were enrolled in 12 German centres and 30 started adjuvant study treatment. Seventeen patients completed all 18 cycles. Two patients terminated study treatment due to adverse events (AEs), 7 due to patient's or investigator's decision and 4 due to recurrence or distant metastasis during adjuvant therapy. Dose levels were reduced to 25 mg/m² in 9 patients, and to 20 mg/m² in 1 patient. Of patients completing all 18 cycles, 5 did so with reduced dosage of S-1. Documented grade ≥ 3 AEs were neutropenia, diarrhoea, vomiting, polyneuropathy, palmar-plantar erythrodysaesthesia and rash. Serious AEs were observed in 7 patients. Median RFS was 32.2 months. One-year relapse-free survival rate was 77%. Data on OS were still premature at the end of the study.\u0000\u0000\u0000CONCLUSION\u0000Adjuvant treatment with S-1 for one year is a feasible and safe treatment option for Caucasian patients diagnosed with gastric adenocarcinoma or cancer of the EGJ cancer after R0-resection.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katell Le Dû, Anne-Lise Septans, Julien Dômont, Olivier Dupuis, Eric Emmanuel, Anne Peribois, Sophie Gaillard, Caroline Allix-Béguec
{"title":"Anaemia in Hospitalized Cancer Patients: A Retrospective Study of Two Cohorts before and after the Guideline Update.","authors":"Katell Le Dû, Anne-Lise Septans, Julien Dômont, Olivier Dupuis, Eric Emmanuel, Anne Peribois, Sophie Gaillard, Caroline Allix-Béguec","doi":"10.1159/000539143","DOIUrl":"10.1159/000539143","url":null,"abstract":"<p><strong>Introduction: </strong>The incidence of anaemia and its consequences are often underestimated during cancer management. We propose to evaluate the situation before and after the recommendations were updated in order to assess their impact on the day-to-day practice.</p><p><strong>Methods: </strong>In this single-centre retrospective study, eligible patients were treated for cancer and warranted overnight hospitalization over two periods (n = 206 in 2011, n = 143 in 2018). The diagnosis of anaemia was defined by a haemoglobin level below 12 and 13 g/dL for women and men, respectively.</p><p><strong>Results: </strong>The prevalence of anaemia was 26% in 2011 and 16% in 2018 (p < 0.001). Biological assessment had changed between the two periods, with more tests of iron metabolism and measurements of inflammatory parameters. Patients hospitalized in 2018 had more advanced cancer and more severe anaemia (8.2 g/dL [±1.07] in 2011 vs. 7.9 g/dL [±1.18] in 2018). Rate of transfusion therapy did not change, but patients with mild and moderate anaemia were transfused less in 2018 (57% in 2011 vs. 44% in 2018). Intravenous iron and erythropoiesis-stimulating agent were used more frequently in 2018 (1 and 5 and 13 and 23% in 2011 and 2018, respectively), mainly for mild anaemia and life-threatening anaemia, respectively. Overall survival was poor in both cohorts at 24 months (15.4% in 2011 and 6.5% in 2018, p = 0.048).</p><p><strong>Conclusion: </strong>Practices have changed in the diagnosis of anaemia and prescriptions for erythropoiesis-stimulating agents and intravenous iron have increased. Efforts must continue to explore the causes of anaemia, optimize patients' quality of life, and reduce transfusions.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Magdalena K Scheck, Ira Ekmekciu, Greta Sommerhäuser, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Henning Wege, Anke Reinacher-Schick, Ralf-Dieter Hofheinz, Thorsten Oliver Götze, Sylvie Lorenzen, Alexander Edward Nieto
{"title":"Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023.","authors":"Magdalena K Scheck, Ira Ekmekciu, Greta Sommerhäuser, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Henning Wege, Anke Reinacher-Schick, Ralf-Dieter Hofheinz, Thorsten Oliver Götze, Sylvie Lorenzen, Alexander Edward Nieto","doi":"10.1159/000538324","DOIUrl":"10.1159/000538324","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140120228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. bis 14. Oktober 2024, Basel.","authors":"","doi":"10.1159/000540557","DOIUrl":"https://doi.org/10.1159/000540557","url":null,"abstract":"<p><p>None.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Golombek, Nora Hegewald, Astrid Schnabel, Hansjakob Fries, Florian Lordick
{"title":"Stability of End-of-Life Care Wishes and Gender-Specific Characteristics of Outpatients with Advanced Cancer under Palliative Therapy: A Prospective Observational Study.","authors":"Thomas Golombek, Nora Hegewald, Astrid Schnabel, Hansjakob Fries, Florian Lordick","doi":"10.1159/000538112","DOIUrl":"10.1159/000538112","url":null,"abstract":"<p><strong>Introduction: </strong>Early integration of palliative care and advance care planning (ACP) play an increasingly important role in the treatment of patients with advanced cancer. Advance directives (ADs) and patients' preferences regarding end-of-life (EoL) care are important aspects of ACP. In the outpatient setting, the prevalence of those documents and EoL care wishes is not well investigated, and changes in the longitudinal course are poorly understood.</p><p><strong>Methods: </strong>From June 2020 to August 2022, 67 outpatients with advanced solid tumors undergoing palliative cancer therapy were interviewed on the topic of ACP in a longitudinal course. From this database, the prevalence of ADs, healthcare proxy, EoL care wishes, and the need for counseling regarding these issues were collected. In addition, EoL care wishes were examined for their stability.</p><p><strong>Results: </strong>Fifty-one patients (76.1%) reported having ADs, and 41 patients (61.2%) reported having a healthcare proxy. Nineteen patients (37.3%) with ADs and 11 patients (68.7%) without ADs indicated a wish for counseling. Reported EoL care wishes remained stable over a period of approximately 6 months. Nevertheless, intraindividual changes occurred over time within the different EoL care preferences. The desire for resuscitation and dialysis were significantly higher in men than in women (resuscitation: 15 of 21 men [71.4%] versus 9 of 22 women [40.9%], odds ratio [OR] 3.611, 95% confidence interval [CI], 1.01-12.89, p = 0.048; dialysis: 16 of the 23 men [69.6%] versus 9 of the 25 women [36.0%], OR: 4.063, 95% CI: 1.22-13.58, p = 0.023).</p><p><strong>Conclusion: </strong>Our results show a reasonably high percentage of ADs and healthcare proxies in our study cohort. The observed stability of EoL requests encourages the implementation of structured queries for ADs and healthcare proxy for outpatients undergoing palliative treatment. Our data suggest that gender-specific characteristics should be further investigated in this context.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giuseppe Bianchi, Maria Antonella Laginestra, Elisa Simonetti, Toni Ibrahim, Fabiana Macrì, Federico Ostetto, Gianmarco Tuzzato, Anna Paioli, Marco Gambarotti, Stefania Cocchi, Davide Maria Donati, Katia Scotlandi, Roberta Laranga
{"title":"Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series.","authors":"Giuseppe Bianchi, Maria Antonella Laginestra, Elisa Simonetti, Toni Ibrahim, Fabiana Macrì, Federico Ostetto, Gianmarco Tuzzato, Anna Paioli, Marco Gambarotti, Stefania Cocchi, Davide Maria Donati, Katia Scotlandi, Roberta Laranga","doi":"10.1159/000540613","DOIUrl":"10.1159/000540613","url":null,"abstract":"<p><strong>Introduction: </strong>Extraskeletal Ewing sarcoma (EEwS) is a rare malignant tumor, and current international recommendations indicate systemic and local treatment like bone Ewing sarcoma (BEwS); to the best of our knowledge, very few studies tried to explore the clinical and genetic characteristics of this tumor, and the most appropriate treatment strategy remains uncertain.</p><p><strong>Methods: </strong>We reviewed 35 EEwS cases enrolled at Rizzoli Orthopedic Institute in Bologna, Italy, between 1988-2022. We performed RNA sequencing in 18 Ewing sarcoma cases, including 12 BEwSs and 6 EEwSs. We analyzed overall survival (OS), local relapse-free survival (LRFS), and metastasis-free survival (MFS) and the risk factors associated to survival.</p><p><strong>Results: </strong>Unsupervised hierarchical clustering showed no differences in the transcriptional profile between EEwS and BEwS. Five-year OS was 67% (95% confidence interval [CI]: 47-80), 5-year LRFS was 61% (95% CI: 43-75), and 5-year MFS was 55% (95% CI: 38-70). Recurrent tumors, larger than 8 cm, and elevated lactate dehydrogenase (LDH) serum value resulted to be negative prognostic factors.</p><p><strong>Conclusions: </strong>The finding/detection of a genetic profile that is indistinguishable between EEwS and BEwS confirms the view that the two subgroups belong to the same tumor entity and supports the use of a single therapeutic approach for Ewing sarcoma, regardless of the site of origin. Statistical evaluation showed that size bigger than 8 cm, elevated LDH, and recurrent tumors had a worse prognosis, suggesting a risk-stratification method for identifying patients for specific therapy treatment. However, larger, multicenter, prospective trials are called for to validate our findings.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141860508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke, Mathias Lutz, Sonja Martin, Paul-Gerhard Schlegel, Roland Schroers, Bastian von Tresckow, Vladan Vucinic, Marion Subklewe, Wolfgang Bethge, Daniel Wolff
{"title":"Management of Patients Undergoing CAR-T Cell Therapy in Germany.","authors":"Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke, Mathias Lutz, Sonja Martin, Paul-Gerhard Schlegel, Roland Schroers, Bastian von Tresckow, Vladan Vucinic, Marion Subklewe, Wolfgang Bethge, Daniel Wolff","doi":"10.1159/000536201","DOIUrl":"10.1159/000536201","url":null,"abstract":"<p><strong>Introduction: </strong>Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin's lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications.</p><p><strong>Methods: </strong>To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers.</p><p><strong>Results: </strong>We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no - or low quality - clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations.</p><p><strong>Conclusion: </strong>The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139417749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}